Policy Watch
In late 2025, UnitedHealthcare announced it would stop covering remote patient monitoring for nearly all conditions starting January 1, 2026 — including chronic hypertension, diabetes, and COPD — affecting millions of Medicare Advantage members. The policy would have limited RPM coverage to only heart failure and pregnancy hypertension patients. The backlash was immediate. Two weeks before the effective date, UHC announced a postponement. But the policy has not been withdrawn — only delayed.
What UHC announced — and why it was legally contested
UnitedHealthcare’s stated rationale was that remote patient monitoring “has no evidence” of effectiveness for the covered conditions. Legal experts immediately challenged this framing. Federal law requires Medicare Advantage plans to cover all services that traditional Medicare covers. CMS covers RPM for patients with acute and chronic conditions under CPT codes 99453, 99454, 99457, and 99458 — coverage that does not restrict by diagnosis. The Alliance for Connected Care and multiple physician groups argued publicly that UHC’s policy directly contravened federal coverage mandates and documented clinical evidence.
Why the delay is not a resolution
UHC’s postponement, announced approximately two weeks before the January 1, 2026 effective date, did not cancel the policy — it deferred it pending additional review. This is significant for two reasons. First, providers who had already made staffing and technology investments based on anticipated RPM coverage faced real uncertainty even during the pause. Second, the episode demonstrates that large private insurers managing Medicare Advantage plans retain substantial unilateral power to narrow access to technology-based care, subject only to regulatory pressure and public backlash — not advance federal approval.
The broader policy implication
The UHC episode is a case study in the structural tension at the center of Medicare Advantage: beneficiaries choose MA plans believing they receive equivalent or enhanced coverage, but plan sponsors retain discretion — within CMS-established bounds — over how that coverage is administered and what evidence standards apply. As RPM utilization expands and OIG oversight of billing irregularities intensifies, other payers may face similar pressure to restrict coverage. Whether CMS will establish clearer and enforceable RPM coverage floors in Medicare Advantage is a central unanswered policy question for 2026 and beyond.